Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20888990 | 0.78 | — | — | |
| SCHEMBL20888662 | 0.75 | TNKS (0.34) | TNKSPARP1TNKS2 | |
| SCHEMBL20888978 | 0.75 | TNKS (0.44) | TNKSPARP1TNKS2 | |
| SCHEMBL20888946 | 0.75 | — | — | |
| SCHEMBL20888985 | 0.73 | ACHE (0.31) | — | |
| SCHEMBL20888947 | 0.70 | — | — | |
| SCHEMBL20888942 | 0.69 | — | — | |
| SCHEMBL20888986 | 0.64 | — | — | |
| SCHEMBL20888983 | 0.63 | — | — | |
| Reproxalap SCHEMBL29536691 | 0.62 | TNKS (0.39) | TNKSPARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | ALDEYRA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230131929-A1 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | ALDEYRA THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11583529-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDEYRA THERAPEUTICS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210393527-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | ALDEYRA THERAPEUTICS, INC. | 2021-11-18 | — | — | US | disclosed |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040039-B2 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200038392-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE | ALDEYRA THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190105322-A1 | Treatment of inflammatory disorders | ALDEYRA THERAPEUTICS, INC. | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131929-A1 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | MAVS, ACE2, SARS1 | TNKS 2314/4885PARP1 810/4885TNKS2 2685/4885 |
| US-11040039-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230293527-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-11583529-B2 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20210347735-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20220133697-A1 | INJECTABLE FORMULATIONS | ALDH2, CLN6, ALDH1A1 | TNKS 4602/4885PARP1 2529/4885TNKS2 4669/4885 |
| US-10550085-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20210353628-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230248727-A1 | TREATMENT OF INFLAMMATORY DISORDERS | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-20230149383-A1 | QUINOLINE COMPOUNDS FOR TREATING LUNG, LIVER, AND KIDNEY DISEASES, DISORDERS, OR CONDITIONS | GLS, PYGL, REN | TNKS 4795/4885PARP1 3708/4885TNKS2 4747/4885 |
| US-20200199075-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20210393527-A1 | PHARMACEUTICAL FORMULATIONS AND USES THEREOF | IL5, CFTR, NQO2 | TNKS 3518/4885PARP1 3098/4885TNKS2 3950/4885 |
| US-20230174491-A1 | DEUTERATED COMPOUNDS AND USES THEREOF | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20190105322-A1 | Treatment of inflammatory disorders | TNF, NFKBIA, LTB4R2 | TNKS 2926/4885PARP1 3007/4885TNKS2 2602/4885 |
| US-11046650-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | TNKS 3071/4885PARP1 736/4885TNKS2 3729/4885 |
| US-20200038392-A1 | TOPICAL COMPOSITIONS AND METHODS OF PREPARATION AND USE | CUTA, TSLP, ASAH2 | TNKS 2853/4885PARP1 4447/4885TNKS2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.